Abnormal monocyte chemotactic response in cancer patients.
Abnormal monocyte chemotactic response in cancer patients.
复制标题
癌症患者单核细胞趋化反应异常。
DOI：
10.1093/jnci/52.4.1091
复制
发表时间：
1974
期刊：
影响因子：
--
通讯作者：
E. Leonard
中科院分区：
文献类型：
--
作者：
D. A. Boetcher;E. Leonard
采用体外单核细胞趋化反应(MCR)检测44例癌症患者的效应细胞功能。44例癌症患者中有24例MCR降低，而22例正常人中有3例降低，24例对照瓣膜病患者中有2例降低。MCR正常的癌症患者的局部感染和/或既往肉芽肿性疾病的发生率明显高于MCR低的患者，这表明癌症患者的感染可能会将低的MCR提高到正常范围。除潘生丁外，许多常见药物对MCR均无影响。MCR异常在微小病变(I期)患者中很少发生，但在所有其他阶段均可发现。在复发转移的黑色素瘤患者中，MCR正常的患者出现淋巴结转移的时间延迟。因此，MCR降低是一种异常，可在人类癌症的自然病程中早期出现，并可能是宿主对疾病反应有效的指标之一。
The in vitro monocyte chemotactic response (MCR) was used to measure effector cell function in 44 cancer patients. Twenty-four of the 44 cancer patients had decreased MCR's, compared to 3 ot 22 normal individuals and 2 of 24 control patients with valvular heart disease. There was a significantly higher incidence of local infection and/or previous granulomatous disease in the cancer patient group with normal MCR's compared to those with low MCR's. This suggests that infection in cancer patients may raise a low MCR to the normal range. Many common medications had no effect on the MCR, with the possible exception of dipyridamole. Abnormal MCR's occurred rarely in patients with minimal disease (stage I), but were found at all other stages. In melanoma patients with recurrent metastatic disease, the appearance of nodal metastases was delayed in patients with normal MCR. Thus decreased MCR is an abnormality that can appear early in the natural history of cancer in humans and may be one indicator ot the effectiveness of host response to the disease.